ArticleOncotarget2013
Tumorigenic potential of circulating prostate tumor cells.
Article in Oncotarget, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.Clinical & experimental metastasis · 2020Review
- Review
- Limiting tumor seeding as a therapeutic approach for metastatic disease.Pharmacology & therapeutics · 2019Review
- Review
- Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy.Molecular cancer research : MCR · 2018Article
- Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management.Biological research · 2018Review
- Circulating tumor cells and their role in prostate cancer.Asian journal of andrology · 2017Review
- Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application.Oncotarget · 2017Article
- Colorectal Cancer Blood-Based Biomarkers.Gastroenterology research and practice · 2017Review
- When Prostate Cancer Circulates in the Bloodstream.Diagnostics (Basel, Switzerland) · 2015Review
- HES6 promotes prostate cancer aggressiveness independently of Notch signalling.Journal of cellular and molecular medicine · 2015Article
- TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer.Oncotarget · 2015Article
- E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis.Oncotarget · 2014Article
- Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.Cancer letters · 2014Article
- Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells.Cell reports · 2014Article
- Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma.Oncotarget · 2014Article
- [Detection of circulating tumor cells from peripheral blood in prostate cancer].Der Urologe. Ausg. A · 2014Review
- Article
- Circulating tumor cells in prostate cancer.Cancers · 2013Article
- Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors.Stem cells translational medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Circulating tumor cells (CTCs) have received intense scientific scrutiny because they travel in the bloodstream and are therefore well situated to mediate hematogenous metastasis. However, the potential of CTCs to actually form new tumors has not been tested. Popular methods of isolating CTCs are biased towards larger, more differentiated, non-viable cells, creating a barrier to testing their tumor forming potential. Without relying on cell size or the expression of differentiation markers, our objective was to isolate viable prostate CTCs from mice and humans and assay their ability to initiate new tumors. Therefore, blood was collected from transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and from human patients with metastatic castration-resistant prostate cancer (PCa). Gradient density centrifugation or red cell lysis was used to remove erythrocytes, and then leukocytes were depleted by magnetic separation using CD45 immunoaffinity beads. CTCs fractions from TRAMP mice and PCa patients were verified by immunocytochemical staining for cytokeratin 8 and EpCAM, and inoculated into immunodeficient mice. TRAMP tumor growth was monitored by palpation. Human tumor growth formation was monitored up to 8 months by ultrasensitive PSA assays performed on mouse serum. We found viable tumor cells present in the bloodstream that were successfully isolated from mice without relying on cell surface markers. Two out of nine immunodeficient mice inoculated with TRAMP CTCs developed massive liver metastases. CTCs were identified in blood from PCa patients but did not form tumors. In conclusion, viable CTCs can be isolated without relying on epithelial surface markers or size fractionation. TRAMP CTCs were tumorigenic, so CTCs isolated in this way contain viable tumor-initiating cells. Only two of nine hosts grew TRAMP tumors and none of the human CTCs formed tumors, which suggests that most CTCs have relatively low tumor-forming potential. Future studies should identify and target the highly tumorigenic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.